Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation, Blood, vol.102, issue.2, pp.592-600, 2003. ,
DOI : 10.1182/blood-2002-10-3161
BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells, Nature Immunology, vol.1, issue.6, pp.526-558, 2000. ,
DOI : 10.1038/82788
Blimp-1 Is Required for the Formation of Immunoglobulin Secreting Plasma Cells and Pre-Plasma Memory B Cells, Immunity, vol.19, issue.4, pp.607-627, 2003. ,
DOI : 10.1016/S1074-7613(03)00267-X
Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program, Immunity, vol.17, issue.1, pp.51-62, 2002. ,
DOI : 10.1016/S1074-7613(02)00335-7
Repression of c-myc Transcription by Blimp-1, an Inducer of Terminal B Cell Differentiation, Science, vol.276, issue.5312, pp.596-605, 1997. ,
DOI : 10.1126/science.276.5312.596
BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle Control, Immunity, vol.13, issue.2, pp.199-212, 2000. ,
DOI : 10.1016/S1074-7613(00)00020-0
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells, Nature, vol.82, issue.7017, pp.635-644, 2004. ,
DOI : 10.1038/ng1018
MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation, Cell, vol.119, issue.1, pp.75-86, 2004. ,
DOI : 10.1016/j.cell.2004.09.014
Blimp-1-Dependent Repression of Pax-5 Is Required for Differentiation of B Cells to Immunoglobulin M-Secreting Plasma Cells, Molecular and Cellular Biology, vol.22, issue.13, pp.4771-80, 2002. ,
DOI : 10.1128/MCB.22.13.4771-4780.2002
Identification of Bach2 as a B-cell-specific partner for small Maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer, The EMBO Journal, vol.17, issue.19, pp.5734-5777, 1998. ,
DOI : 10.1093/emboj/17.19.5734
Failure of B-cell differentiation in mice lacking the transcription factor EBF, Nature, vol.376, issue.6537, pp.263-270, 1995. ,
DOI : 10.1038/376263a0
Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function, Science, vol.275, issue.5299, pp.540-543, 1997. ,
DOI : 10.1126/science.275.5299.540
Differential requirement for OBF-1 during antibody-secreting cell differentiation, The Journal of Experimental Medicine, vol.58, issue.9, pp.1385-96, 2005. ,
DOI : 10.1023/A:1009843325770
Dec1 and Dec2 are regulators of the mammalian molecular clock, Nature, vol.20, issue.6909, pp.841-845, 2002. ,
DOI : 10.1074/jbc.274.10.6043
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts, Blood, vol.100, pp.1113-1135, 2002. ,
Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression, Blood Cells, Molecules, and Diseases, vol.32, issue.2, pp.293-301, 2004. ,
DOI : 10.1016/j.bcmd.2003.12.001
Phenotypic characterization of the human myeloma cell growth fraction, Blood, vol.105, issue.12, pp.4845-4853, 2005. ,
DOI : 10.1182/blood-2004-12-4700
Identification and characterization of plasma cells in normal bone marrow by high resolution flow cytometry, pp.1739-1747, 1990. ,
Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6, Blood, vol.92, pp.3887-97, 1998. ,
Purification of human tonsil plasma cells: Pre-enrichment step by immunomagnetic selection of CD31+ cells, Cytometry, vol.32, issue.3, pp.231-235, 2000. ,
DOI : 10.1002/(SICI)1097-0320(20000301)39:3<231::AID-CYTO9>3.0.CO;2-G
Molecular Profiling of Newly Diagnosed Multiple Myeloma, Blood, vol.98, p.733, 2001. ,
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response, Blood, vol.105, issue.4, pp.1614-1635, 2005. ,
DOI : 10.1182/blood-2004-07-2507
Plasma-cell homing, Nature Reviews Immunology, vol.3, issue.10, pp.822-831, 2003. ,
DOI : 10.1038/nri1203
The Chemokine Receptor CXCR4 Is Required for the Retention of B Lineage and Granulocytic Precursors within the Bone Marrow Microenvironment, Immunity, vol.10, issue.4, pp.463-71, 1999. ,
DOI : 10.1016/S1074-7613(00)80046-1
A Coordinated Change in Chemokine Responsiveness Guides Plasma Cell Movements, The Journal of Experimental Medicine, vol.95, issue.1, pp.45-56, 2001. ,
DOI : 10.4049/jimmunol.165.6.3423
Chemokines and Cell Migration in Secondary Lymphoid Organs, Science, vol.286, issue.5447, pp.2098-102, 1999. ,
DOI : 10.1126/science.286.5447.2098
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-780, 2001. ,
DOI : 10.1182/blood.V98.3.771
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.97, issue.26, pp.9991-9997, 2003. ,
DOI : 10.1073/pnas.211566398
Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, vol.368, issue.6469, pp.339-342, 1994. ,
DOI : 10.1038/368339a0
IgG1 plasmacytosis in interleukin 6 transgenic mice., Proceedings of the National Academy of Sciences, vol.86, issue.19, pp.7547-7551, 1989. ,
DOI : 10.1073/pnas.86.19.7547
Interleukin-6 is a growth factor for nonmalignant human plasmablasts, Blood, vol.97, issue.6, pp.1817-1839, 2001. ,
DOI : 10.1182/blood.V97.6.1817
New insights into the pathophysiology of multiple myeloma, The Lancet Oncology, vol.4, issue.9, pp.557-64, 2003. ,
DOI : 10.1016/S1470-2045(03)01195-1
THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASE, Annual Review of Cell and Developmental Biology, vol.20, issue.1, pp.781-810, 2004. ,
DOI : 10.1146/annurev.cellbio.20.010403.113126
Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand, Blood, vol.97, issue.11, pp.3349-53, 2001. ,
DOI : 10.1182/blood.V97.11.3349
A molecular compendium of genes expressed in multiple myeloma, Blood, vol.100, issue.6, pp.2175-86, 2002. ,
DOI : 10.1182/blood-2002-01-0008
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans, Nature Genetics, vol.53, issue.8, pp.820-828, 2005. ,
DOI : 10.1038/ng1600
APRIL: A Tutorial on B Cell Survival, Annual Review of Immunology, vol.21, issue.1, pp.231-64, 2003. ,
DOI : 10.1146/annurev.immunol.21.120601.141152
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells, The Journal of Experimental Medicine, vol.157, issue.1, pp.91-99, 2004. ,
DOI : 10.1038/nsb769
The BAFF/APRIL system: life beyond B lymphocytes, Molecular Immunology, vol.42, issue.7, pp.763-72, 2005. ,
DOI : 10.1016/j.molimm.2004.06.041
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, 2005. ,
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406
Identification of proteoglycans as the APRIL-specific binding partners, The Journal of Experimental Medicine, vol.103, issue.9, pp.1375-83, 2005. ,
DOI : 10.1002/eji.1830221136
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens, Human Pathology, vol.30, issue.12, pp.1405-1416, 1999. ,
DOI : 10.1016/S0046-8177(99)90160-0
Proximal promoter of the murine syndecan-1 gene is not sufficient for the developmental pattern of syndecan expression in B lineage cells, American Journal of Hematology, vol.272, issue.1, pp.20-26, 2001. ,
DOI : 10.1002/ajh.1071
Large scale and clinical grade purification of syndecan-1+ malignant plasma cells, Journal of Immunological Methods, vol.205, issue.1, pp.73-79, 1997. ,
DOI : 10.1016/S0022-1759(97)00056-2
Functions of Cell Surface Heparan Sulfate Proteoglycans, Annual Review of Biochemistry, vol.68, issue.1, pp.729-77, 1999. ,
DOI : 10.1146/annurev.biochem.68.1.729
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins, Blood, vol.96, pp.2528-2564, 2000. ,
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis, Nature, vol.398, pp.723-731, 1999. ,
Mechanism of Stimulation of Osteoclastic Bone Resorption through Gas6/Tyro 3, a Receptor Tyrosine Kinase Signaling, in Mouse Osteoclasts, Journal of Biological Chemistry, vol.276, issue.10, pp.7376-82, 2001. ,
DOI : 10.1074/jbc.M007393200
Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family, Science, vol.293, issue.5528, pp.306-317, 2001. ,
DOI : 10.1126/science.1061663
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis, Nature Medicine, vol.7, issue.2, pp.215-236, 2001. ,
DOI : 10.1038/84667
Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway, Blood, vol.95, pp.633-641, 2000. ,
Expression of the Receptor Tyrosine Kinase Axl Promotes Ocular Melanoma Cell Survival, Cancer Research, vol.64, issue.1, pp.128-162, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-0245
XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor, Cell, vol.107, issue.7, pp.881-91, 2001. ,
DOI : 10.1016/S0092-8674(01)00611-0
Plasma cell differentiation requires the transcription factor XBP- 1, Nature, vol.412, issue.6844, pp.300-307, 2001. ,
DOI : 10.1038/35085509
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1, Nature Immunology, vol.4, issue.4, pp.321-330, 2003. ,
DOI : 10.1038/ni907
XBP1, Downstream of Blimp-1, Expands the Secretory Apparatus and Other Organelles, and Increases Protein Synthesis in Plasma Cell Differentiation, Immunity, vol.21, issue.1, pp.81-93, 2004. ,
DOI : 10.1016/j.immuni.2004.06.010
XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response, Molecular and Cellular Biology, vol.23, issue.21, pp.7448-59, 2003. ,
DOI : 10.1128/MCB.23.21.7448-7459.2003
CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum, Genes & Development, vol.18, issue.24, pp.3066-77, 2004. ,
DOI : 10.1101/gad.1250704
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation, Blood, vol.80, pp.2326-2335, 1992. ,
Stem-cell transplantation in multiple myeloma, Best Practice & Research Clinical Haematology, vol.18, issue.4, pp.603-621, 2005. ,
DOI : 10.1016/j.beha.2005.01.005
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, New England Journal of Medicine, vol.341, issue.21, pp.1565-71, 1999. ,
DOI : 10.1056/NEJM199911183412102
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, New England Journal of Medicine, vol.348, issue.26, pp.2609-2626, 2003. ,
DOI : 10.1056/NEJMoa030288
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, Blood, vol.106, issue.1, pp.35-44, 2005. ,
DOI : 10.1182/blood-2005-02-0522
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-573, 2002. ,
DOI : 10.1056/NEJMoa01133202
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report, Cancer Research, vol.64, issue.4, pp.1546-58, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-2876
Molecular aspects of multiple myeloma, Molecular Pathology, vol.55, issue.5, pp.273-83, 2002. ,
DOI : 10.1136/mp.55.5.273
Hypodiploidy is a major prognostic factor in multiple myeloma, Blood, vol.98, issue.7, pp.2229-2267, 2001. ,
DOI : 10.1182/blood.V98.7.2229
Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases, Genes, Chromosomes and Cancer, vol.98, issue.3, pp.234-243, 2003. ,
DOI : 10.1002/gcc.10275
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, vol.102, issue.7, pp.2562-2569, 2003. ,
DOI : 10.1182/blood-2003-02-0493
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, Leukemia, vol.19, issue.2, pp.275-283, 2005. ,
DOI : 10.1038/sj.leu.2403586
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics, Genes, Chromosomes and Cancer, vol.40, issue.2, 2005. ,
DOI : 10.1002/gcc.20231
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma, Leukemia, vol.17, issue.10, pp.2032-2037, 2003. ,
DOI : 10.1038/sj.leu.2403091
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy, Blood, vol.100, issue.5, pp.1579-83, 2002. ,
DOI : 10.1182/blood-2002-03-0749
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, vol.106, issue.8, 2005. ,
DOI : 10.1182/blood-2005-04-1411
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma, Proceedings of the National Academy of Sciences, vol.86, issue.11, pp.13931-13936, 1996. ,
DOI : 10.1016/0092-8674(82)90137-4
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, vol.106, issue.8, 2005. ,
DOI : 10.1182/blood-2005-04-1411
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation, Blood, vol.103, issue.11, pp.4056-61, 2004. ,
DOI : 10.1182/blood-2003-12-4435
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy, Blood, vol.92, pp.802-809, 1998. ,
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation, Blood, vol.105, issue.1, pp.358-60, 2005. ,
DOI : 10.1182/blood-2004-04-1363
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells, Blood, vol.99, issue.5, pp.1745-57, 2002. ,
DOI : 10.1182/blood.V99.5.1745
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development, Blood, vol.101, issue.3, pp.1128-1168, 2003. ,
DOI : 10.1182/blood-2002-06-1737
Multiple Myeloma, Hematology, vol.2004, issue.1, pp.237-56 ,
DOI : 10.1182/asheducation-2004.1.237
URL : https://hal.archives-ouvertes.fr/inserm-00479729
The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression, Current Opinion in Hematology, vol.9, issue.4, pp.288-93, 2002. ,
DOI : 10.1097/00062752-200207000-00005
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript, Blood, vol.101, issue.6, pp.2374-2380, 2003. ,
DOI : 10.1182/blood-2002-09-2801
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, vol.106, issue.1, pp.296-303, 2005. ,
DOI : 10.1182/blood-2005-01-0034
A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival, Blood, vol.104, 2004. ,
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression, Blood, vol.101, issue.10, pp.3849-56, 2003. ,
DOI : 10.1182/blood-2002-09-2873
Multiple myeloma: global expression profiling indicates upregulation of the ribosomal machinery in hyperdiploid clones, Blood, vol.1004, p.1421, 2004. ,
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma, pp.219-223, 1988. ,
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-97, 2000. ,
DOI : 10.1038/sj.leu.2401632
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma, Blood, vol.95, pp.2630-2636, 2000. ,
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma, Blood, vol.93, pp.3064-73, 1999. ,
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion, Blood, vol.82, pp.3712-3720, 1993. ,
NF-??B as a Therapeutic Target in Multiple Myeloma, Journal of Biological Chemistry, vol.277, issue.19, pp.16639-16686, 2002. ,
DOI : 10.1074/jbc.M200360200
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model, Cancer Research, vol.64, issue.6, pp.2016-2039, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-1131
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma, Cancer Cell, vol.5, issue.2, pp.191-200, 2004. ,
DOI : 10.1016/S1535-6108(04)00019-4
Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3, British Journal of Cancer, vol.88, issue.6, pp.855-62, 2003. ,
DOI : 10.1038/sj.bjc.6600833
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma, Blood, vol.100, pp.2195-202, 2002. ,
Homing behaviour of the malignant cell clone in multiple myeloma, Medical Oncology, vol.16, issue.3, pp.154-64, 1998. ,
DOI : 10.1007/BF02821934
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor, Leukemia, vol.18, issue.5, pp.976-82, 2004. ,
DOI : 10.1038/sj.leu.2403331
Survival and Proliferation Factors of Normal and Malignant Plasma Cells, International Journal of Hematology, vol.276, issue.2, pp.106-113, 2003. ,
DOI : 10.1007/BF02983377
URL : https://hal.archives-ouvertes.fr/inserm-00130900
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas, Nature, vol.332, issue.6159, pp.83-85, 1988. ,
DOI : 10.1038/332083a0
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989. ,
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma, European Journal of Immunology, vol.76, issue.1, pp.1759-62, 1991. ,
DOI : 10.1002/eji.1830210727
Survival and proliferation factors of human myeloma cells, Recent Advances in the Biology of Multiple Myeloma, 2003. ,
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004. ,
DOI : 10.1182/blood-2003-05-1510
URL : https://hal.archives-ouvertes.fr/inserm-00130207
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone, Blood, vol.103, issue.8, pp.3148-57, 2004. ,
DOI : 10.1182/blood-2003-06-1984
URL : https://hal.archives-ouvertes.fr/inserm-00129502
Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells, Oncogene, vol.21, issue.16, pp.2584-2592, 2002. ,
DOI : 10.1038/sj.onc.1205355
EGF receptor ligands, Experimental Cell Research, vol.284, issue.1, pp.2-13, 2003. ,
DOI : 10.1016/S0014-4827(02)00105-2
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, The EMBO Journal, vol.16, issue.7, pp.1647-55, 1997. ,
DOI : 10.1093/emboj/16.7.1647
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells, Oncogene, vol.83, issue.21, pp.3512-3536, 2005. ,
DOI : 10.1038/sj.onc.1208536
URL : https://hal.archives-ouvertes.fr/inserm-00130206
Identification of intercellular communication signals involved in multiple myeloma with microarrays, Haematologica/the hematology journal, vol.100, 2005. ,
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells, Nature, vol.393, pp.83-88, 1998. ,
Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells, Cancer Res, vol.61, pp.383-91, 2001. ,
Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-?? signaling complex, Oncogene, vol.22, issue.23, pp.3598-607, 2003. ,
DOI : 10.1038/sj.onc.1206512
Small Molecules with EGFR-TK Inhibitor Activity, Current Drug Targets, vol.6, issue.3, pp.259-74, 2005. ,
DOI : 10.2174/1389450053765888
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival, Blood, vol.103, issue.2, pp.689-94, 2004. ,
DOI : 10.1182/blood-2003-06-2043
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2483-94, 2003. ,
DOI : 10.1056/NEJMoa030847
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells, Proceedings of the National Academy of Sciences, vol.17, issue.4, pp.6122-6129, 2004. ,
DOI : 10.1038/sj.leu.2402875
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays, Oncogene, vol.99, issue.44, pp.6848-6857, 2002. ,
DOI : 10.1038/sj.onc.1205868
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation, Blood, vol.106, issue.1, pp.59-66, 2005. ,
DOI : 10.1182/blood-2004-09-3645
Amphiregulin Is a Novel Growth Factor Involved in Normal Bone Development and in the Cellular Response to Parathyroid Hormone Stimulation, Journal of Biological Chemistry, vol.280, issue.5, pp.3974-81, 2005. ,
DOI : 10.1074/jbc.M409807200